Guang'anmen Hospital, China Academy of Chinese Medical Science, Beijing 100053, China.
Evid Based Complement Alternat Med. 2012;2012:931636. doi: 10.1155/2012/931636. Epub 2011 Aug 22.
Objectives. To assess the beneficial and adverse effects of Xiaoyaosan for depression. Search Strategy. Electronic databases were searched until December 2009. Inclusion Criteria. We included randomized clinical trials testing Xiaoyaosan against placebo, antidepressants, or combined with antidepressants against antidepressants alone. Data Extraction and Analyses. Study selection, data extraction, quality assessment, and data analyses were conducted according to the Cochrane standards. Results. 26 randomized trials (involving 1837 patients) were included and the methodological quality was evaluated as generally low. The pooled results showed that Xiaoyaosan combined with antidepressants was more effective in comprehensive effect, the score of HAMD and the score of SDS compared with antidepressants alone. Xiaoyaosan was superior to antidepressants for the score of HAMD. However, Xiaoyaosan was not different from placebo for the score of SDS. There was no adverse effects reported in the trials from Xiaoyaosan. Conclusions. Xiaoyaosan appears to be effective on improving symptoms in patients with depression. However, due to poor methodological quality in the majority of included trials, the potential benefit from Xiaoyaosan need to be confirmed in rigorous trials and the design and reporting of trials should follow international standards.
目的。评估逍遥散治疗抑郁症的疗效和安全性。
检索策略。电子数据库检索至 2009 年 12 月。
纳入标准。纳入与安慰剂、抗抑郁药或与抗抑郁药联合治疗比较的逍遥散治疗抑郁症的随机临床试验。
数据提取和分析。根据 Cochrane 标准进行研究选择、数据提取、质量评估和数据分析。
结果。共纳入 26 项随机试验（涉及 1837 例患者），方法学质量普遍较低。汇总结果显示，逍遥散联合抗抑郁药在综合疗效、HAMD 评分和 SDS 评分方面优于抗抑郁药单独治疗。逍遥散在 HAMD 评分方面优于抗抑郁药。然而，在 SDS 评分方面，逍遥散与安慰剂无差异。试验中未报告逍遥散的不良反应。
结论。逍遥散似乎能有效改善抑郁症患者的症状。但是，由于大多数纳入试验的方法学质量较差，需要在严格的试验中证实逍遥散的潜在益处，并且试验的设计和报告应遵循国际标准。
